Compare iShares MBS ETF (MBB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Medtronic PLC — how do they compare? iShares MBS ETF trades at $89.7 (market cap $35.45B), while Medtronic PLC trades at $87.64 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 3.1× iShares MBS ETF's market cap, and Medtronic PLC pays a 3.37% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Medtronic PLC for 63 Days on average.
| MBB | MDT | |
|---|---|---|
Market Cap | $35.45B | $109.38B |
Volume | 4,982,386 | 55,890,185 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $105.35 |
52-Week Low | $89.09 | $73.75 |
Typical Hold Time | 96 Days | 63 Days |
Enterprise Value | — | $128.71B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB, the iShares MBS ETF, trades at $89.22, down 0.16% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The ETF faces headwinds from rising intermediate-term rates and inflation, as noted in recent analysis, while short interest has surged significantly. Recent corporate actions include scheduled dividend payments, but key financial ratios are not available in the provided data.
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. Investment opportunities exist for income-focused investors attracted to its dividend yield, but risks include further rate hikes and prepayment volatility. Investors should weigh the ETF's role in a diversified fixed income portfolio against potential duration-related losses.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
